About 50–70% of prostate carcinomas harbor common chromosomal rearrangements fusing one of the ETS transcription family genes (ERG, ETV1, ETV4 or FLI1) with androgen-regulated genes, most commonly TMPRSS2, leading to disruption of androgen receptor signaling via activation of EZH253. Here, ERG is linked to prostate carcinoma.